Latest results about emerging MS therapies, risk factors, disease mechanisms, rehabilitation, CCSVI, and much more presented at AAN Meeting
Nearly 12,000 neurologists and investigators convened in New Orleans in April to present findings at the American Academy of Neurology’s annual meeting. Over 500 scientific presentations and display posters focused on research to stop MS, restore fun...
Read MoreUPDATE: U.S. FDA and European Medicine Agency Update Prescribing Recommendations for Gilenya to Better Manage Potential Heart Risks at the Time the First Dose Is Taken
The FDA and the EMA have revised prescribing information for the oral MS therapy Gilenya. The recommendations were based on independent safety reviews initiated by the agencies after deaths had been reported among patients taking Gilenya. The revised ...
Read MoreSmall Study Reports Benefit of Marijuana on MS Spasticity
A small clinical trial by California investigators found some benefit of smoked marijuana against spasticity (muscle tightness and spasms) and pain in people with MS. Participants also experienced significantly reduced thinking ability after smoking ma...
Read MoreSpeeding Clinical Trials for People with Progressive MS: Outcomes Published from an International Workshop on MS Disability Measurement Tools
Disease progression, or gradual worsening, experienced by people who have multiple sclerosis usually occurs over many years, and it is difficult to track with the standard clinical measurement scales used by doctors to assess disease activity. An inter...
Read More